New Year's Stocks Traders and Investors Should Know About: (NASDAQ: AEZS), (NYSE: WFR)
AEterna Zentaris Inc. (USA) (NASDAQ: AEZS) 2.47 +0.30 (13.82%) The company announced that the FDA supports a phase 3 trial of its drug AEZS-108, a potential treatment for endometrial cancer. The U.S.-listed shares of Canadian drugmaker Aeterna Zentaris Inc surged after the company said it had reached an agreement with the U.S. Food and Drug Administration on a special protocol assessment by the FDA for a Phase 3 registration trial in endometrial cancer with AEZS-108 treatment.
View full press release